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Background and purpose
Health-related Quality of Life (HRQOL) in children with
juvenile idiopathic arthritis (JIA) is significantly impaired
due to pain, joint damage and inflammation. The purpose
of this study was to examine the effect of abatacept treat-
ment in JIA patients on HRQOL, pain and sleep quality.
Methods
190 JIA patients were treated with abatacept for 4 months
in an open-label lead-in period (Period A). ACR Pedi 30
responders (n = 123) were then randomized 1:1 to receive
abatacept or placebo for up to 6 months in a double-blind
withdrawal period (Period B). HRQOL was assessed by
the Child Health Questionnaire (CHQ), sleep quality was
measured by the Children's Sleep Habits Questionnaire
(CSHQ), and pain by a 0–100 mm VAS. Mean change
from baseline in each period was calculated and com-
pared between the treatment groups (in Period B), and the
change over time was examined.
Results
At study entry patients had considerably lower HRQOL
than the general population. After 4 months of abatacept
treatment in Period A, substantial improvements were
seen across all patient reported measures. Improvements
in CHQ scores were statistically significant in 14 out of 15
health concepts, with the greatest increase in the physical
domain. Pain and sleep problems were statistically signif-
icantly reduced. At the end of Period B, most abatacept
patients maintained or continued these improvements,
while placebo patients generally experienced declining
HRQOL, increased pain and sleep problems.
Conclusion
Abatacept treatment significantly improved multiple
aspects of HRQOL, pain, and sleep quality in JIA patients.
Such improvements were prolonged with continued
abatacept therapy.
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